Preview

Вестник трансплантологии и искусственных органов

Расширенный поиск

РЕВАСКУЛЯРИЗАЦИЯ МИОКАРДА В ЛЕЧЕНИИ ПАЦИЕНТОВ С СИСТОЛИЧЕСКОЙ ДИСФУНКЦИЕЙ ЛЕВОГО ЖЕЛУДОЧКА: СОСТОЯНИЕ ПРОБЛЕМЫ

https://doi.org/10.15825/1995-1191-2013-2-156-163

Полный текст:

Аннотация

Результаты реваскуляризации миокарда у пациентов с хронической систолической дисфункцией левого желудочка при ишемической болезни сердца до сих пор неоднозначны. Выявление нефункционирую- щего, но жизнеспособного миокарда, который способен восстановиться после реваскуляризации, очень важно в определении прогноза лечения. Гибернирующий миокард может быть выявлен различными ме- тодами, и его наличие и распространенность являются предиктором функционального и структурного восстановления после реваскуляризации. Новые устройства и методики лечения улучшают прогноз, что подтверждено рядом клинических исследований. Рандомизированное исследование для оценки эффек- тивности коронарной реваскуляризации у пациентов с хронической дисфункцией левого желудочка, по- лучающих оптимальное медикаментозное лечение и новейшие устройства, объективно необходимо. 

Об авторе

А. Б. Миронков
ГБУЗ «Городская клиническая больница No 12 Департамента здравоохранения Москвы» (гл. врач – к. м. н. А.В. Саликов), Москва, Российская Федерация


Список литературы

1. Adams Jr K.F., Fonarow G.C., Emerman C.L. Charac- teristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preli- minary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE) // Am. Heart. J. 2005; 149: 209–216.

2. Gheorghiade M., Bonow R.O. Chronic heart failure in the United States: a manifestation of coronary artery di- sease // Circulation. 1998; 97: 282–289.

3. Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т. Первые результаты национального эпидемиологического обследования – эпидемиологическое обследование больных ХСН в реальной практике (по обращаемос- ти) – ЭПОХА–О–ХСН // Сердечная недостаточность. 2003; 4 (3): 116–120.

4. Belenkov Y.N., Mareev V.Y., Ageev F.T. The first results of a national epidemiological study – epidemiological stu- dy of patients with CHF in real practice (referral) – the EPOHA-O-HSN study // Serdechnaya Nedostatochnost’. 2003; 4 (3): 116–120.

5. Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т. Эпидемио- логическое исследование сердечной недостаточнос- ти: состояние вопроса // Сердечная недостаточность. 2002. 10: 57–58.

6. Belenkov Y.N., Mareev V.Y., Ageev F.T. Epidemiological study heart failure: problem statement // Serdechnaya Nedostatochnost’. 2002; 10: 57–58.

7. Horn H.R., Teichholz L.E., Cohn P.F., Herman M.V., Gorlin R. Augmentation of left ventricular contraction pattern in coronary artery disease by an inotropic cate- cholamine: The epinephrine ventriculogram // Circulati- on. 1974; 49: 1063–1071.

8. Helfant R.H., Pine R., Meister S.G., Feldman M.S., Trout R.G., Banka V.S. Nitroglycerin to unmask rever- sible asynergy: Correlation with post coronary bypass ventriculography // Circulation. 1974; 50: 108–113.

9. Wijns W., Vatner S.F., Camici P.G. Hibernating myocar- dium // N. Engl. J. Med. 1998; 339: 173–181.

10. Camici P.G., Prasad S.K., Rimoldi O.E. Stunning, hiber- nation and assessment of myocardial viability // Circula- tion. 2008; 117: 103–114.

11. Diamond G.A., Forrester J.S., de Luz P.L., Wyatt H.L., Swan H.J. Postextrasystolic potentiation of ischemic myocardium by atrial stimulation // Am. Heart. J. 1978; 95: 204–209.

12. Rahimtoola S.H. A perspective on the three large multi- center randomized clinical trials of coronary bypass sur-

13. gery for chronic stable angina // Circulation. 1985; 72:

14. V123–V135.

15. Uren N.G., Melin J.A., De Bruyne B., Wijns W., Baud-

16. huin T., Camici P.G. Relation between myocardial blood flow and the severity of coronary-artery stenosis // N. Engl. J. Med. 1994; 330: 1782–1788.

17. Tillisch J., Brunken R., Marshall R., Schwaiger M., Man- delkern M., Phelps M. Reversibility of cardiac wall-mo- tion abnormalities predicted by positron tomography // N. Engl. J. Med. 1986; 314: 884–888.

18. Schinkel A.F., Bax J.J., Poldermans D., Elhendy A., Ferrari R., Rahimtoola S.H. Hibernating myocardium: Diagnosis and patient outcomes // Curr. Probl. Cardiol. 2007; 32: 375–410.

19. Bateman T.M., Heller G.V., McGhie A.I., Friedman J.D., Case J.A., Bryngelson J.R. Diagnostic accuracy of rest/stress ECG-gated Rb-82 myocardial perfusion PET: Comparison with ECG-gated Tc-99 m sestamibi SPECT // J. Nucl. Cardiol. 2006; 13: 24–33.

20. Ghosh N., Rimoldi O.E., Beanlands R.S., Camici P.G. Assessment of myocardial ischaemia and viability: Role of positron emission tomography // Eur. Heart. J. 2010. [E-pub ahead of print].

21. Marinho N.V., Keogh B.E., Costa D.C., Lammerst- ma A.A., Ell P.J., Camici P.G. Pathophysiology of chro- nic left ventricular dysfunction: New insights from the measurement of absolute myocardial blood flow and glu- cose utilization // Circulation 1996; 93: 737–744.

22. CASS. Coronary artery surgery study (CASS): A rando- mized trial of coronary artery bypass surgery: Survival data // Circulation. 1983; 68: 939–950.

23. Wijns W., Kolh P., Danchin N., Di Mario C., Falk V., Folliguet T. Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) // Eur. Heart. J. 2010 [E-pub ahead of print].

24. McMurray J.J. Clinical practice: Systolic heart failure // N. Engl. J. Med. 2010; 362: 228–238.

25. Dickstein K., Cohen-Solal A., Filippatos G., McMur- ray J.J., Ponikowski P., Poole-Wilson P.A. ESC Guideli- nes for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology: Developed in collabora- tion with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) // Eur. Heart. J. 2008; 29: 2388–2442.

26. Velazquez E.J., Lee K.L., O’Connor C.M., Oh J.K., Bo- now R.O., Pohost G.M. The rationale and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trial // J. Thorac. Cardiovasc. Surg. 2007; 134: 1540–1547.

27. Boden W.E., O’Rourke R.A., Teo K.K., Hartigan P.M., Maron D.J., Kostuk W.J. Optimal medical therapy with or without PCI for stable coronary disease // N. Engl. J. Med. 2007; 356: 1503–1516.

28. Hochman J.S., Lamas G.A., Buller C.E., Dzavik V., Rey- nolds H.R., Abramsky S.J. Coronary intervention for per- sistent occlusion after myocardial infarction // N. Engl. J. Med. 2006; 355: 2395–2407.

29. Frye R.L., August P., Brooks M.M., Hardison R.M., Kel- sey S.F., MacGregor J.M. A randomized trial of thera- pies for type 2 diabetes and coronary artery disease // N. Engl. J. Med. 2009; 360: 2503–2515.

30. Erne P., Schoenenberger A.W., Burckhardt D., Zuber M., Kiowski W., Buser P.T. Effects of percutaneous coronary interventions in silent ischemia after myocardial infarc- tion: The SWISSI II randomized controlled trial. JAMA. 2007; 297: 1985–1991.

31. Alderman E.L., Bourassa M.G., Cohen L.S., Davis K.B., Kaiser G.G., Killip T. Ten-year follow-up of survival and myocardial infarction in the randomized Coronary Arte- ry Surgery Study // Circulation. 1990; 82: 1629–1646.

32. Pitt B., Waters D., Brown W.V., van Boven A.J., Schwartz L., Title L.M. Aggressive lipid-lowering thera- py compared with angioplasty in stable coronary artery disease: Atorvastatin versus Revascularization Treat- ment Investigators // N. Engl. J. Med. 1999; 341: 70–76.

33. Shaw L.J., Berman D.S., Maron D.J., Mancini G.B., Hayes S.W., Hartigan P.M. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: Results from the Clinical Out- comes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy // Circu- lation. 2008; 117: 1283–1291.

34. Chaitman B.R., Hardison R.M., Adler D., Gebhart S., Grogan M., Ocampo S. The Bypass Angioplasty Revas- cularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: Impact of treatment strategy on cardiac mortality and myocardial infarction // Circulation. 2009; 120: 2529–2540.

35. Cantor W.J., Baptista S.B., Srinivas V.S., Pearte C.A., Menon V., Sadowski Z. Impact of stress testing before percutaneous coronary intervention or medical manage- ment on outcomes of patients with persistent total oc- clusion after myocardial infarction: Analysis from the occluded artery trial // Am. Heart. J. 2009; 157: 666–672.

36. Allman K.C., Shaw L.J., Hachamovitch R., Udelson J.E. Myocardial viability testing and impact of revasculari- zation on prognosis in patients with coronary artery di- sease and left ventricular dysfunction: A meta-analysis // J. Am. Coll. Cardiol. 2002; 39: 1151–1158.

37. Tarakji K.G., Brunken R., McCarthy P.M., Al-Cheka- kie M.O., Abdel-Latif A., Pothier C.E. Myocardial viabi- lity testing and the effectof early intervention in patients with advanced left ventricular systolic dysfunction // Circulation. 2006; 113: 230–237.

38. PackerM.,CoatsA.J.,FowlerM.B.,KatusH.A.,KrumH., Mohacsi P. Effect of carvedilol on survival in severe chro- nic heart failure // N. Engl. J. Med. 2001; 344: 1651–1658.

39. Ellenbogen K.A., Wood M.A., Klein H.U. Why should we care about CARE-HF? // J. Am. Coll Cardiol. 2005; 46: 2199–2203.

40. Sata Y., Krum H. The future of pharmacological therapy for heart failure // Circ. J. 2010; 74: 809–817.

41. Fox K., Garcia M.A., Ardissino D., Buszman P., Cami- ci P.G., Crea F. Guidelines on the management of stable angina pectoris: Executive summary: The Task Force on the Management of Stable Angina Pectoris of the Euro-

42. pean Society of Cardiology // Eur. Heart. J. 2006; 27:

43. –1381.

44. Kruk M., Buller C.E., Tcheng J.E., Dzavik V., Menon V.,

45. Mancini G.B. Impact of left ventricular ejection fraction on clinical outcomes over five years after infarct-related coronary artery recanalization (from the Occluded Arte- ry Trial [OAT]) // Am. J. Cardiol. 2010; 105: 10–16.

46. Dzavik V., Buller C.E., Lamas G.A., Rankin J.M., Manci- ni G.B., Cantor W.J. Randomized trial of percutaneous co- ronary intervention for subacute infarct-related coronary artery occlusion to achieve long-term patency and improve ventricular function: The Total Occlusion Study of Canada (TOSCA)-2 trial // Circulation. 2006; 114: 2449–2457.

47. Kirschbaum S.W., Springeling T., Boersma E., Moel- ker A., van der Giessen W.J., Serruys P.W. Complete percutaneous revascularization for multivessel disease in patients with impaired left ventricular function: Pre- and post-procedural evaluation by cardiac magnetic resonance imaging JACC // Cardiovasc Interv. 2010; 3: 392–400.

48. Cleland J.G., Pennell D.J., Ray S.G., Coats A.J., Macfar- lane P.W., Murray G.D. Myocardial viability as a deter- minant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): Rando- mised controlled trial // Lancet. 2003; 362: 14–21.

49. Beanlands R.S., Nichol G., Huszti E., Humen D., Raci- ne N., Freeman M. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and su- spected coronary disease: A randomized, controlled trial (PARR-2) // J. Am. Coll. Cardiol. 2007; 50: 2002–2012.

50. Abraham A., Nichol G., Williams K.A., Guo A., deKemp R.A., Garrard L. 18F-FDG PET imaging of myocardial viability in an experienced center with ac- cess to 18F-FDG and integration with clinical manage- ment teams: The Ottawa-FIVE substudy of the PARR 2 trial // J. Nucl. Med. 2010; 51: 567–574.

51. D’Egidio G., Nichol G., Williams K.A., Guo A., Gar- rard L., deKemp R. Increasing benefit from revasculari- zation is associated with increasing amounts of myocar- dial hibernation: A substudy of the PARR-2 trial // JACC Cardiovasc. Imaging. 2009; 2: 1060–1068.

52. Jones R.H., Velazquez E.J., Michler R.E., Sopko G., Oh J.K., O’Connor C.M. Coronary bypass surgery with or without surgical ventricular reconstruction // N. Engl. J. Med. 2009; 360: 1705–1717.

53. Serruys P.W., Morice M.C., Kappetein A.P., Colombo A., Holmes D.R., Mack M.J. Percutaneous coronary interven- tion versus coronary-artery bypass grafting for severe coro- nary artery disease // N. Engl. J. Med. 2009; 360: 961–972.

54. Cleland J.G., Daubert J.C., Erdmann E., Freemantle N., Gras D., Kappenberger L. The effect of cardiac resyn- chronization on morbidity and mortality in heart failu- re // N. Engl. J. Med. 2005; 352: 1539–1549.

55. Moss A.J., Zareba W., Hall W.J., Klein H., Wilber D.J., Cannom D.S. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejec- tion fraction // N. Engl. J. Med. 2002; 346: 877–883.

56. Moss A.J. What we have learned from the family of mul- ticenter automatic defibrillator implantation trials // Circ. J. 2010; 74: 1038–1041.


Для цитирования:


Миронков А.Б. РЕВАСКУЛЯРИЗАЦИЯ МИОКАРДА В ЛЕЧЕНИИ ПАЦИЕНТОВ С СИСТОЛИЧЕСКОЙ ДИСФУНКЦИЕЙ ЛЕВОГО ЖЕЛУДОЧКА: СОСТОЯНИЕ ПРОБЛЕМЫ. Вестник трансплантологии и искусственных органов. 2013;15(2):156-163. https://doi.org/10.15825/1995-1191-2013-2-156-163

For citation:


Mironkov A.B. MYOCARDIAL REVASCULARIZATION IN PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION: PROBLEM STATEMENT. Russian Journal of Transplantology and Artificial Organs. 2013;15(2):156-163. (In Russ.) https://doi.org/10.15825/1995-1191-2013-2-156-163

Просмотров: 562


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-1191 (Print)
ISSN 2412-6160 (Online)